BBNX · Beta Bionics
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $22.81
Note written ·
Price against the kill line
28.0% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $22.81, on record since 11 November 2026. The shares are down 6.5% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $22.81, the highest close of the last 63 sessions (22 September 2026), would show the shares leading the S&P 500 and prove this call wrong, as would 2026 revenue above the $126 million top of the guide.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 27 October 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 35.5
- Revenue, change on a year (%)
- +30.3
- Gross margin (%)
- 57.3
- Operating margin (%)
- −74.9
- Free cash flow, four quarters ($M)
- −66.0
- Net cash, cash less debt ($M)
- 219
- Enterprise value to sales (×)
- 5.3
- Free-cash-flow yield (%)
- −7.4
All filed numbers
What Beta Bionics reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 35.5 | +30.3 | 57.3 | −74.9 |
| first filed | 32.0 | +37.8 | 59.0 | −79.9 |
| first filed | 27.6 | +56.6 | 59.5 | −87.9 |
| first filed | 32.1 | +57.1 | 59.0 | −50.2 |
| first filed | 27.3 | +63.1 | 55.5 | −62.5 |
| first filed | 23.2 | +54.4 | 53.8 | −85.5 |
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −83.1 | −24.4 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +6.7 |
| Operating cash flow ($M) | −59.4 |
| Capital spending ($M) | 6.6 |
| Free cash flow ($M) | −66.0 |
| Cash and short-term investments ($M) | 240 |
| Debt ($M) at 31 December 2025, filed 24 February 2026; credit line | 0.1 |
| Net cash, cash less debt ($M) at 31 December 2025, filed 27 October 2026 | 219 |
| Deferred revenue ($M) +27.7% on a year | 5.5 |
| Backlog, orders not yet delivered ($M) +53.8% on a year | 2.0 |
| Receivables ($M) | 20.7 |
| Inventory ($M) | 23.0 |
| Shareholders' equity ($M) | 401 |
| Market value ($M) | 893 |
| Enterprise value, market value plus net debt ($M) | 674 |
| Enterprise value to sales (×) | 5.3 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 2.2 |
| Free-cash-flow yield (%) | −7.4 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 12.7% of shares outstanding sold short, 7.4 days of average trading to cover, +14.4% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $2.6M |
| 12 monthsfrom | $0 | $4.7M |
The thesis
Beta Bionics' shares are more likely to lag the S&P 500 over the next three months. The case depends on the Mint patch pump, which reaches full U.S. launch only in the first quarter of 2027, while iLet buyers hold back orders in the fourth quarter of 2026. The rating is Low because the next quarter is guided to be a demand pause. The company's own data on Mint shipments and payer coverage, due with fourth-quarter results in early 2027, settle the case.
The third-quarter report on 27 October 2026 beat estimates. Sales were $35.505 million against $34.722 million expected, and the loss was $0.52 per share against $0.53 expected (Benzinga). The company narrowed 2026 revenue guidance to $124–126 million from $121–126 million. It also cut its estimate of fourth-quarter revenue that could slip into 2027 to up to $8.5 million from up to $10 million. Earnings Whispers reported that management guided fourth-quarter new patient starts down about 20% from the third quarter, and the shares fell 16.55% on 28 October 2026.
The shares closed at $17.81 on 11 November 2026, up from $16.52 on 10 November 2026, on the day management presented at the Stifel Healthcare Conference. The company issued no release with the move. One rising session after a 6 November 2026 close of $15.70 does not change the fourth-quarter demand picture.
The market prices a slow Mint ramp. The 11 November 2026 close is 45.6% below the 52-week intraday high of $32.71 set on 26 November 2025, and MarketBeat's average analyst target was $23.69 on 11 November 2026.
Bullish and bearish views on Beta Bionics, Inc.
The bull case on Beta Bionics, Inc. (BBNX), in brief: funding is in place. The bear case: fourth-quarter demand is guided down.
Bull case
- Funding is in place. Cash and investments were $373.6 million at 30 September 2026, up from $225.2 million at 30 June 2026, after a $161.3 million net equity raise (company results release, 27 October 2026).
- Pharmacy sales keep compounding. Pharmacy-channel net sales were $13.6 million in the third quarter of 2026, up 118% year over year. Total net sales were $35.5 million, up 30% (Q3 release, 27 October 2026).
- Deferral is smaller than feared. Management now sees up to $8.5 million of fourth-quarter iLet revenue deferred, down from up to $10 million, because fewer buyers are waiting than expected (Q3 call, 27 October 2026). It expects to recapture that revenue in 2027.
- New patient starts rose in the third quarter. Starts grew by a mid-single-digit percentage from the second quarter, and 69% came from people switching from multiple daily injections (Q3 release, 27 October 2026).
- Analysts mostly rate the shares a buy. MarketBeat counted 10 buy or strong-buy ratings, 4 holds and 1 sell among 15 analysts on 11 November 2026. Piper Sandler reiterated Overweight with a $24 target and TD Cowen kept Hold with a target raised to $21 on 28 October 2026.
Bear case
- Fourth-quarter demand is guided down. Earnings Whispers reported management guided fourth-quarter new patient starts down about 20% from the third quarter as buyers wait for Mint (28 October 2026).
- Margins slipped. Gross margin was 57.3% in the third quarter, below 59.0% in the second. The full-year guide of 58.5–59.5% needs a fourth-quarter rebound, and management said Mint will dilute gross margin in 2027 (Q3 call, 27 October 2026).
- Mint starts small. Output begins near zero on one manufacturing line and builds through 2027, per the Q3 call on 27 October 2026. The 3D software versions of iLet and Mint await FDA clearance under a 510(k) submission.
- Share count has grown. Shares outstanding were 54.4 million at 30 September 2026, up from 44.4 million at year-end 2025. The 16 September 2026 offering at $17.25 also included pre-funded warrants for 1,043,484 shares.
- Losses are widening. The third-quarter net loss was $24.4 million, against $14.2 million a year earlier (company release, 27 October 2026).
- Insiders keep selling small lots. SEC Form 4 filings show the chief product officer sold 2,650 shares at $22.00 on 27 October 2026, the chief commercial officer 370 shares at $16.90 on 2 November 2026 and the chief financial officer 382 shares at $17.04 on 5 November 2026, all under Rule 10b5-1 plans.
Price setup
The shares closed at $17.81 on 11 November 2026. That is 1.5% lower over three months against the 13 August 2026 close of $18.08. The close sits below the 50-day moving average of $18.6 and above the 200-day moving average of $14.8, both as of 11 November 2026 on adjusted daily closes.
The levels the case turns on are close together. The $17.25 price of the 16 September 2026 offering is just under the last close, and the shares closed below it from 4 November 2026 through 10 November 2026. The 52-week closing low is $8.86 on 10 April 2026, before Mint's clearance on 14 September 2026. Above the price, the highest close of the 63 sessions to 11 November 2026 came on 22 September 2026.
The next earnings report is expected around February 2027 and has no announced date. Until then, conference remarks and any FDA clearance of the 3D software are the only scheduled sources of new information.
Catalysts ahead
- 18 November 2026: Jefferies Global Healthcare Conference, London (investor meetings through 19 November 2026). Management commentary on Mint production and early pharmacy coverage ahead of the launch.
- 2 December 2026: Piper Sandler Healthcare Conference presentation. A last scheduled read on fourth-quarter new patient starts and the size of iLet revenue deferral before year end.
- ~31 December 2026 (est.): iLet 3D launch, pending FDA 510(k) clearance of 3D Intelligence software. A clearance gives iLet buyers an upgrade to buy now instead of waiting for Mint; a delay extends the demand pause.
- ~February 2027 (est.): Q4 and full-year 2026 results. Shows whether 2026 revenue lands inside the $124–126M guide and gives the first numbers on Mint's launch.
- ~31 March 2027 (est.): Full U.S. commercialization of Mint (company-guided for Q1 2027). The event the case depends on; a slip would extend deferred iLet demand.
What would change the view
A daily close above $22.81, the highest close of the last 63 sessions (22 September 2026), would show the shares leading the S&P 500 and prove this call wrong, as would 2026 revenue above the $126 million top of the guide.
What it trades with
Beta Bionics competes with Insulet and Tandem Diabetes Care, the two larger insulin-pump makers. Insulet reported third-quarter 2026 revenue of $842.0 million, up 19.2%, and is the incumbent in patch pumps that Mint targets. Tandem reported third-quarter sales of $283.7 million in its 8-K. Beta Bionics' own price has moved mainly on company events: the 14 September 2026 Mint clearance and guidance cut, the 16 September 2026 offering and the 27 October 2026 report. Moves in the larger pump makers have mattered less to it.
The evidence, claim by claim (8)
- Q3 2026 net sales were $35.5M, up 30% YoY; pharmacy-channel sales $13.6M (+118%); gross margin 57.3%; net loss $24.4M. Beta Bionics Q3 2026 results release / 8-K · as of
- 2026 revenue guidance narrowed to $124–126M from $121–126M; up to $8.5M of Q4 revenue may be deferred, down from up to $10M. Beta Bionics Q3 2026 release and earnings call · as of
- Q3 EPS of −$0.52 against −$0.53 estimate; sales of $35.505M against $34.722M estimate. Benzinga earnings summary · as of
- Cash and investments were $373.6M at 30 September 2026 after a $161.3M net equity raise; shares outstanding were 54.4M versus 44.4M at year-end 2025. Beta Bionics Q3 2026 results release · as of
- Mint full U.S. commercialization planned for Q1 2027; output starts near zero on one manufacturing line; Mint gross margin dilutive in 2027. Q3 2026 earnings call (MarketBeat transcript highlights) · as of
- Shares fell 16.55% on 28 October 2026; fourth-quarter new patient starts guided down about 20% sequentially. Earnings Whispers via finviz · as of
- MarketBeat consensus: 15 analysts, 10 buy or strong buy, 4 hold, 1 sell; average 12-month target $23.69. MarketBeat analyst consensus report · as of
- CFO Stephen Feider exercised and sold 382 shares at $17.04 on 5 November 2026 under a Rule 10b5-1 plan. SEC Form 4 filed 9 November 2026 · as of
Sources
- Beta Bionics, Inc. - Form 8-K - FY2026 · sec.gov
- MarketBeat ·
- Finviz
- Beta Bionics, Inc. (NASDAQ:BBNX) Stock Rated "Moderate Buy" by Wall Street Brokerages · marketbeat.com ·
- BioPharmaWatch
- FDA clears reusable insulin patch pump for people with diabetes · healio.com ·
- Insulet reports third quarter 2026 results · finviz.com
- TANDEM DIABETES CARE INC - Form 8-K - FY2026 · sec.gov
Related · shared themes
CDNA
CareDx
CareDx's shares are modestly more likely than not to beat the S&P 500: transplant testing revenue grew 39% in the third quarter excluding…
GRAL
GRAIL
GRAIL's shares are more likely to lag the S&P 500 over three months: after a 78.8% three-month rise, approval of the Galleri cancer test…
QDEL
QuidelOrtho
QuidelOrtho's shares are more likely to lag the S&P 500: third-quarter revenue fell 11.6% and net leverage rose to 4.5 times while the…
PLSE
Pulse Biosciences
Pulse Biosciences is modestly more likely to lead the S&P 500 because $189.2 million of cash funds its atrial-fibrillation catheter through…
See also · stocks to watch